Article
Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
Neuro-oncology - 1 Jul 2012
Künkele Annette, De Preter Katleen, Heukamp Lukas, Thor Theresa, Pajtler Kristian W, Hartmann Wolfgang, Mittelbronn Michel, Grotzer Michael A, Deubzer Hedwig E, Speleman Frank, Schramm Alexander, Eggert Angelika, Schulte Johannes H
Abstract excerpt
Medulloblastomas account for 20% of pediatric brain tumors. With an overall survival of 40%-70%, their treatment is still a challenge. The majority of medulloblastomas lack p53 mutations, but even in cancers retaining wild-type p53, the tumor surveillance function of p53 is inhibited by the oncoprotein MDM2. Deregulation of the MDM2/p53 balance leads to malignant transformation. Here, we analyzed MDM2 mRNA and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.